Fig. 3

T_PH enrichment analysis in the synovial membrane of the external dataset reproduces the patterns observed in our patient cohort. a PD-1^hiCXCR5-CD4+ cell percentage quantified using immunofluorescence on synovial biopsies of our patient cohort at week 20 of anti-TNF therapy. b PD-1^hiCXCR5-CD4+ cell enrichment levels estimated using the cell-type deconvolution approach on the external patient cohort at week 12 of anti-TNF therapy. In both cases, EULAR good responders show distinctively lower T_PH cell levels than moderate or none responders (P = 3.5e−4 and P = 4e−3 for our patient cohort and the external RA patient cohort, respectively)